Vertex Builds Type 1 Diabetes Reach And Flexibility With ViaCyte

 
• By Jessica Merrill

Vertex will pay $320m to buy rival ViaCyte, which is developing stem cell therapies for type 1 diabetes, to complement internal work on VX-880, the firm announced.

multiple pawns
Vertex wants to expand its Type 2 diabetes options • Source: Shutterstock

More from Deals

More from Business